Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
RSI on SPY is 45 in negative territory first time in a while for sure. QQQ rsi is 48 MACD is negative
Blackout period is until April 26
IWM rsi is 40
TZA
SQQQ
SPXU
80% of companies can’t do stock repurchases this week so first bigger pullback since October 2023 could be coming. Equity gains could cool off. Healthy reset for market chance to buy dips.
Silver alert could the Mexican supply alert change pricing …Mike Maloney
No doing cash is king thanks for PRZO we shall find some more
PRZO Out at $1 lol fortunately got busy
TPET .38 boom HNRA PRZO
PRZO .81 sneaking in with some volume 10m floaters
EFSH 2.70s Did in some 2.30s EFSH nice low floater and moving with small volume
HNRA 2.77 start cashing in some chips and see if next resistance challenged
TMF more then likely building $46 may have been bottom with China CPI dropping badly despite all the stimulus during Chinese new year see a rate drop in June…lol
China slowdown going to hit US soon and lots of Big Actors doing business in China Walmart Apple Microsoft etc
GDXU all out at $44s hard to see $46 hitting but still possible. Will start looking for GDXD potential entry on the pullback side
EZGO 1.68 to 3.42 not bad up 100% on robots are coming.. lol imagine all the police pensions they could get rid of ..EZGO Enters into an RMB13 Million Procurement Agreement for Sale of Security Patrol Robots and Platform
Source: PR Newswire (US)
CHANGZHOU, China, April 12, 2024 /PRNewswire/ -- EZGO Technologies Ltd. (Nasdaq: EZGO) ("EZGO" or "we," "our," or the "Company"), a leading short-distance transportation solutions provider in China, today announced that it entered into a procurement agreement (the "Procurement Agreement") with Hangzhou Huiyu Zhichuang Industrial Co., Ltd. ("Huiyu Zhichuang"), a subsidiary of Huiyu Holdings Group ("Huiyu Group"), which is a China-based company primarily engaged in real estate development business and ranked one of the top 500 civilian-run enterprises in China, for the sale of twelve security patrol robots (the "Robots") and one intelligent patrol platform (together with the Robots, the "Products") for an aggregate sales price of RMB 13.46 million (approximately US$1.84 million). The entry of the Procurement Agreement demonstrates market recognition of the Company's strong R&D and manufacturing capabilities.
Pursuant to the Procurement Agreement, the Company agrees to complete the delivery and installation of the Products within 9 months after the execution of the Procurement Agreement. The Robots stand out with a myriad of modern features, including self-navigation, live video streaming, proficient face and license plate detection, vocal notifications, an emergency SOS button, self-charging capabilities, infrared vision, and full compatibility with smart patrol systems. This suite of features reinforces EZGO's efforts to advancements in short-distance transport solutions.
Mr. Jianhui Ye, Chairman and Chief Executive Officer of the Company, commented, "This sale once again showcases the appeal of our products and our ability to continuously acquire new customers. In September 2023, we successfully delivered 10 Robots to PIESAT Information Technology Co., Ltd. Keeping the good momentum, the transaction with Huiyu Zhichuang is expected to help us expand businesses with Huiyu Group and achieve sustained orders and sales in other industrial parks under its management. The twelve Robots purchased by Huiyu Zhichuang will be used for intelligent security patrols in Huiyu Intelligent Innovation Park, an industrial park in Hangzhou, Zhejiang, China with a gross floor area of 189,564 square meters to attract digital economy enterprises as its tenants.
Meanwhile, this sale further solidifies our position and drives us to remain at the forefront of smart transportation solutions. It also indicates the successful execution of our marketing strategy of appealing to and growing sales to a more diversified group. We look forward to securing more contracts in the future, delivering exceptional value to our clients, and consequently creating substantial value for our shareholders."
About EZGO Techn
YANG 11.68 + 8% China worst CPI in 20 years and PPI down 5 months in a row will have a global effect including US..tic toc tic toc ..disinflation on the way after crude oil cools down for sure
HNRA 2.64
BTTR $7 in some $6s 300k floater and lawsuit go well together for a potential scalp.. $6.10 support stop loss 6.62 - 6.72 next minor support. Also will eventually need volume
NEW YORK, March 26, 2024 (GLOBE NEWSWIRE) -- Better Choice Company, Inc. (NYSE: BTTR) (“Better Choice” or the “Company”), a pet health and wellness company, initiated a legal action to enforce a right of first refusal (“ROFR”) option exercised by Alphia, Inc. (“Alphia”) BL4424547, which is controlled by a Paris-based private equity firm, PAI Partners (https://www.paipartners.com). Pursuant to the terms of a written agreement between Alphia and the Company, Alphia is obligated to acquire the assets of Halo, Purely for Pets, Inc., a wholly owned subsidiary of Better Choice. Better Choice seeks to compel the closing of the asset sale and, in the alternative, monetary damages in excess of $19 million caused by Alphia for its misconduct in connection with the ROFR. “After several unsuccessful attempts to communicate with both Winston Song of PAI Partners and David McLain, the CEO of Alphia, and given the significant burden imposed upon Better Choice by Alphia’s refusal to close the transaction, Better Choice had no viable option other than to pursue legal action to enforce the terms of the ROFR, as well as all of its rights,” stated Better Choice Chairman, Michael Young. The claim has been filed in the Circuit Court of the 13th Judicial Circuit in and for Hillsborough County, Florida.
About Better Choice Company, Inc.
PXMD HNRA 2.50s resistance for HNRA 2.61- 2.96 then a $3 breaks sees $3.40
PXMD stay above 1.09 for the 4hr and 1.70s next
ALLR 3.84
ALLR 3.62
ALLR 3.49 200k float ..round 2 start cashing some chips again
ALLR 2.60s round 2 ready
TMF hit $48 can flip some $46s here and wait for the dip again or just hold em
CISS 1.99 wait until end of day for cheapies reverse split completed
PXMD NXPL BENF ALLR HUBC ZPTA TPET HKD VIAO MI
Paxmedica IncPXMD
1.15 +177.11% 31.86M
Nextplat CorpNXPL
2.47 +63.58% 18.84M
BeneficientBENF
0.11 +64.98% 53.31M
Allarity Therapeut.ALLR
2.83 +23.00% 3.9M
Hub Cyber SecurityHUBC
1.44 +23.08% 4.1M
Zapata Computing H.ZPTA
3.10 +24.00% 7.1M
Trio PetroleumTPET
0.2944 +24.75% 19.24M
AMTD DigitalHKD
3.91 +23.34% 872.63K
Via Optronics AgVIAO
0.56 +21.74% 45.94K
Nft LtdMI
5.85 +3,934.48% 6.69K
GDXU nice $42 out of some more next levels to watch 43.17 and 46.36.
After China CPI PPI report TMF should hold support at $46 for entry
NRXP 6.77 + 22% break 7.01 then 8.90 up next 6m
Float .. There are medicines available to help manage the highs and lows of bipolar disorder, but not a single-dose treatment. Typically, it requires one to manage mania and another for depression. They may not work for everyone and come with their own set of side effects.
Modifying The NMDA Receptor
NRx Pharmaceuticals Inc.
, a clinical-stage biopharmaceutical company, believes it has the answer with NRX-101. It's the biopharmaceutical company's FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. The company is targeting life-threatening diseases that often go untreated with NRX-101, which is a patented, oral fixed-dose combination of two FDA-approved drugs: D-cycloserine, an NMDA receptor modulator at certain dosage ranges; and Lurasidone, a 5-HT2a receptor antagonist.
Combined, the drugs target the NMDA receptor which is critical for memory function and the formation of new thoughts in the brain. At excessive rates of NMDA activity, ideas including the creation of new ones are slowed down. People with bipolar disorder tend to ruminate on fewer and more negative thoughts in that state. When the NMDA channel is blocked, thoughts can flow rapidly and incoherently, leading to hallucinations and psychosis. The challenge is to strike a healthy balance between the two. By modulating the NMDA, NRx believes it can improve the function of the thought-forming cells in the brain and thus reduce suicidal ideation. If approved by the U.S. Food and Drug Administration (FDA) and other health regulatory agencies, the company says it would be the first medicine regimen targeted to treat severe bipolar depression in patients with both acute and sub-acute suicidal ideation or behavior (ASIB and SSIB).
Trial Over-Enrolled
The company is taking steps to make that a reality, recently completing enrollment of a phase 2b/3 study of NRX-101 for 74 patients suffering from bipolar disorder. Enrollment exceeded the original target of 70 patients, to enhance the statistical power of the study, NRx said. Top-line data is expected later this month.
“To our knowledge, NRX-101 is the first and only oral medication to have demonstrated reduced suicidal ideation in patients with bipolar depression," said Dr. Jonathan Javitt, Founder, Chairman and Chief Scientist of NRx Pharmaceuticals. "On the basis of our previous trial, it was awarded Breakthrough Therapy Designation by the FDA and we aim to confirm its effect on depression and suicidal ideation in this trial."
NRX teamed up with Alvogen Pharmaceuticals for the development and marketing of the combined therapy. During its fourth quarter, NRx said Alvogen advanced its first $5.1 million milestone payment. A successful readout from the phase 2b trial and FDA interaction will trigger an additional $4 million milestone payment together with the transfer of future development costs to Alvogen. The partnership provides for potential milestones of $329 million and a royalty reaching 15% on net sales, according to NRx.
Beyond Bipolar Disorder
It's not just bipolar disorder that NRx is aiming to treat with its NMDA therapy platform. The company is making inroads in using its lead compound in chronic pain, betting results of a 200-person efficacy trial conducted by Northwestern University could create a multibillion-dollar opportunity for NRx. Chronic pain is another condition that plagues more than 50 million Americans in which the available treatments have mixed results.
Then there's its new drug application for IV ketamine in acute suicidality. NRx said it is building a specialty pharmaceutical business around ketamine it expects to yield positive cash flow by the end of 2024. Called HOPE Therapeutics, NRx plans to submit a new drug application with the FDA this year. In advance of FDA approval, HOPE partnered with national 503b and 503a pharmacies to address the ketamine shortage reported by the FDA since 2018. The goal is to spin HOPE out into a stand-alone company owned by NRx, current NRx shareholders via a tax-free dividend and new investors. NRx said prospective anchor investors offered $60 million in new investment dollars once HOPE is publicly listed. NRx said HOPE is presenting data from four randomized, prospective trials demonstrating safety and efficacy in 800 patients as the clinical basis for its new drug application (NDA) for HTX-100 (IV Ketamine).
And if that's not enough, NRx recently received Qualified Infectious Disease Product (QIDP) and Fast Track designation from the FDA for NRX-101 in the treatment of complicated urinary tract infections (cUTI) and pyelonephritis. It’s a condition the company says affects 3 million people in the U.S. resulting in over 15,000 deaths annually. NRx is currently seeking partners with active involvement in urology, infectious disease and/or women’s health for commercialization of NRX-101.
“2023 was a pivotal year for NRx in which we advanced from a single clinical trial in a single indication to a dramatically streamlining operation with a 50% reduction in overhead costs, a 25% reduction in overall costs and a $0.20 per share improvement in negative earnings, while completing our clinical trial objectives," says Stephen Willard, J.D., Chief Executive Officer and Director of NRx Pharmaceuticals. ‘We expect data from two key trials this month and predict our first commercial revenue by the end of 2024."
ZPTA NXPL OCX HKD NRXP LYEL GL NEXT IINN XXII LGVN RR GDXU
ALLR $4.06 hit that 200k float
MI 1 to 50 reverse split .80
Hit it 200k float
China CPI fell by 1% about the most in 20 years and PPI was down 0.01% for 5th month in a row …so will the Fed do a rate cut sooner then later ..probably..
China largest importer of crude oil saw imports drop as industrial production dropped so this is disinflationary
CNY down = BAD News for World
Yes you did alert PXMD
PXMD nice one 1.09 resistance
Economy is robust lol with car dealerships new and used closing down at record paces 2008 reenactment and car repos running at 50,000 per day. Banks won’t lend and finance to cats and dogs nor should they have been allowed but government allowed it..
Housing markets in Texas Austin so many listings it’s a buyers markets 35,000 to 131,000 sellers sitting with unsold properties
Ride it saddle up $7s CADL…Co announced that the FDA has granted Orphan Drug Designation to CAN-2409, Candel's most advanced multimodal biological immunotherapy candidate, for the treatment of pancreatic cancer.
NVDA boom boom Nasdaq anything NVDA related will follow soon enough.. dips dips.
All that matters is the weekly 5ema on SPX which has held every week miraculously PPT plunge protection team since November and tomorrow Friday …lol 401k day.
Rally rally lol
Well you’re fine on HYMC sit back and have some AMC popcorn now and see how the movie plays out. Was another moon market pick you were in